



Supplementary Data: Elinzanetant (NT-814), a Non-Hormonal Neurokinin 1,3 Receptor Antagonist, Reduces Estradiol and Progesterone in Healthy Women

Supplementary Figure 1: The change from baseline in serum LH (IU/L) on assessment days 3/4, 9/10, 15/16 and 21/22 in healthy women after placebo (N=8, red), elinzanetant 40 mg (N=7, blue), 80 mg (N=8, green) and 120 mg (N=8, orange). Scatter dot plot depicts individual participants with median and interquartile range for each timepoint and treatment group.



Supplementary Figure 2A: The median averaged across all time points during Cycle 1 (C1) and Cycle 2 (C2) in serum progesterone (nmol/L) in healthy women after placebo (N=8, red), elinzanetant 40 mg (N=7, blue), 80 mg (N=8, green) and 120 mg (N=8, orange). Data in graphs depict within-participant paired raw data and the group median and interquartile range.



Supplementary Figure 2B: The median change across all time points between Cycle 1 and Cycle 2 in serum progesterone (nmol/L) in healthy women after placebo (N=8, red), elinzanetant 40 mg (N=7, blue), 80 mg (N=8, green) and 120 mg (N=8, orange).

